Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depres… (NCT05915013) | Clinical Trial Compass
RecruitingPhase 1
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
United States50 participantsStarted 2023-09-07
Plain-language summary
The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.
Who can participate
Age range18 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria Substudy #2:
* Right-handed as determined by the Edinburgh Handedness Inventory
* Current depression as indicated by a score greater than 17 on the full Hamilton Depression Rating Scale
* Anti-depressant resistant depressive symptoms, defined by a history of failure of one or more adequate anti-depressant trials
* Individuals who have previously received ketamine must have had a positive response. Individuals who report reduced depressive symptoms will be treated as ketamine responders and entered directly into the closed label trial.
* Participants will meet DSM-5 Criteria for MDD as determined by the SCID-5
* All participants given ketamine must be engaged in treatment outside of the research protocol. Those who are not currently in treatment may be referred for treatment.
* Individuals who are receiving pharmacotherapy for depression must have been receiving the current medication and dose for 4 weeks before randomization. In addition, they should have a plan to continue the current regime of pharmacotherapy for the duration of the trial.
* Individuals who are receiving psychotherapy must have been in treatment for four weeks and should have a plan to continue the current regime of psychotherapy for the duration of the trial.
* Willing to refrain from caffeine, drug and alcohol use for one week prior to each MRI session
* Females will be included if they are not pregnant or breastfeeding and agree to utilize a medically accepted birth control method (to…
What they're measuring
1
Prefrontal functional connectivity
Timeframe: During ketamine infusion, approximately 2.5 hours
2
Cerebral metabolic rate of oxygen (CMRO2)
Timeframe: During ketamine infusion, approximately 2.5 hours.